The American Heart Association statistics indicate that roughly 2,300 Americans die from cardiovascular disease or stroke every day and an estimated 92 million more are currently living with some form of the disease.
Simon Stertzer, MD, who serves as Professor Emeritus at Stanford University School of Medicine recently discussed the potential of biotechnology to transform how heart disease is treated and prevented. Additionally, as the co-founder of BioCardia, a clinical stage regenerative biotechnology company, Stertzer is uniquely qualified to provide insight on the topic.
Given the speed of healthcare innovation, and longer life-spans thanks to advancements in medicine, Dr. Stertzer noted that new cell therapy treatments could have an impact on the heart failure population but also “meticulous attention to blood pressure, diet, physical activity, and blood lipid treatments” are measures that can “delay or decrease the numbers of increasing heart failure in post heart attack victims.”
In addition to changing personal habits and increased monitoring by physicians, patients are empowered now more than ever. From new technology like the FitBit Charge 3, which includes an SpO2 sensor notifying users of potential health concerns, to stem cell research like that of BioCardia, these innovations are revolutionizing the healthcare industry and patient care.
Read the rest of the interview to learn Dr. Simon Stertzer’s take on healthcare innovation in 2018.
For more insights from Simon Stertzer, read his recent interview with The Sanity Snack.